Sanjay Chanda - 15 Mar 2024 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role: Chief Development Officer
Signature: /s/ Lucy Day, Attorney-in-Fact for Sanjay Chanda
Issuer symbol: ANTX
Transactions as of: 15 Mar 2024
Net transactions value: $0
Form type: 4
Filing time: 18 Mar 2024, 19:27:34 UTC
Previous filing: 17 Feb 2023
Next filing: 07 Jan 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ANTX	Common Stock	Award	$0	+27,500	+3741%	$0.000000	28,235	15 Mar 2024	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ANTX	Stock Option (right to buy)	Award	$0	+55,000		$0.000000	55,000	15 Mar 2024	Common Stock	55,000	$3.00	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These restricted stock units vest as follows: 1/16th of the shares vests quarterly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.
F2	Reflects the adjusted total which includes the purchase of 735 shares under the AN2 Therapeutics, Inc. 2022 Employee Stock Purchase Plan on September 29, 2023.
F3	The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.